NCT06337175CompletedPhase 4
Predictors of Post-alteplase Hemorrhagic Transformation of Brain Infarction
Predictors of Post-alteplase Different Subtypes of Hemorrhagic Transformation of Brain Infarction in the Middle East
Source: ClinicalTrials.gov · Last updated 5 Sept 2025
Brief summary (registry, in English)
The investigators evaluated whether the characteristics of ischemic stroke patients, door-to-needle time, and stroke risk factors were predictive variables for different subtypes of post-alteplase hemorrhagic transformation of brain infarction.
- Status (registry)
- Completed
- Phase (registry)
- Phase 4
- Study type
- Interventional
- Enrollment
- 600 (actual)
- First submitted
- 22 Mar 2024
- Start date
- 1 Jun 2021
- Primary completion date
- 30 Oct 2023
- Lead sponsor
- Kafrelsheikh University
- Diseases
- Stroke
- NCT number
- NCT06337175
What you commit to
- Study type: Interventional · Phase 4
- Participants enrolled: 600
- From 1 Jun 2021 to the primary completion date, 30 Oct 2023
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- The investigators excluded patients with symptoms of major organ failure, active malignancies, or an acute myocardial infarction within the previous six weeks.
Other illness
- The investigators excluded patients with a known history of persistent or recurrent CNS pathology (e.g., epilepsy, meningioma, multiple sclerosis, history of head trauma with a residual neurological deficit).
- The investigators excluded patients who had recurrent ischemic stroke diagnosed by appropriate clinical history and/or MRI brain findings.
- The investigators also excluded pregnant and lactating patients with stroke due to venous thrombosis and stroke following cardiac arrest
Other
- The investigators excluded patients who had not been followed up on for 90 days after enrollment,
- Those with alteplase contraindications or did not receive the total dose of alteplase due to any reason were excluded
Who the study is looking for
- The investigators enrolled individuals of both genders, aged between 18 and 75, who presented with acute first-ever ischemic stroke and were eligible for thrombolysis.
Age in the registry: 18 years to 75 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Kafr-Elsheikh University Hospital Coordinator of this site? Confirm its status | Kafr ash Shaykh | Egypt | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.